Top news
All coverage
Rare disease deal: Biogen buys Hibio for $1.15B up front
By Lee Landenberger
Biogen acquires Hi-Bio, California biotech, for $1.15 billion
By jonathan saltzman
Biogen to buy immune drug developer HI-Bio (NASDAQ:BIIB)
By Dulan Lokuwithana
Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio
By Allison DeAngelis
Biogen to buy Peninsula startup developing a drug for kidney disease for $1.2 billion
By Hannah Green
Biogen maintains stock target with Buy rating on acquisition intention By Investing.com
By Natashya Angelica
IGM Biosciences up 40% following Biogen HI-Bio buy
By Jonathan Block